GCLLSG Prognostic Index
. | Score . | 5-y survival, % . |
---|---|---|
Biomarker | ||
Age, y | ||
≤60 | 0 | |
>60 | 1 | |
Sex | ||
Female | 0 | |
Male | 1 | |
ECOG PS | ||
0 | 0 | |
>0 | 1 | |
β2-microglobulin, mg/L | ||
≤1.7 | 0 | |
1.7-3.5 | 1 | |
>3.5 | 2 | |
Serum thymidine kinase, U/L | ||
≤10 | 0 | |
>10 | 2 | |
IGHV | ||
Mutated | 0 | |
Unmutated | 1 | |
11q22-q23 | ||
Nondeleted | 0 | |
Deleted | 1 | |
17p13 | ||
Nondeleted | 0 | |
Deleted | 6 | |
Risk group | ||
Low risk | 1-2 | 95 |
Intermediate risk | 3-5 | 86 |
High risk | 6-10 | 67 |
Very-high risk | 11-14 | 18 |
. | Score . | 5-y survival, % . |
---|---|---|
Biomarker | ||
Age, y | ||
≤60 | 0 | |
>60 | 1 | |
Sex | ||
Female | 0 | |
Male | 1 | |
ECOG PS | ||
0 | 0 | |
>0 | 1 | |
β2-microglobulin, mg/L | ||
≤1.7 | 0 | |
1.7-3.5 | 1 | |
>3.5 | 2 | |
Serum thymidine kinase, U/L | ||
≤10 | 0 | |
>10 | 2 | |
IGHV | ||
Mutated | 0 | |
Unmutated | 1 | |
11q22-q23 | ||
Nondeleted | 0 | |
Deleted | 1 | |
17p13 | ||
Nondeleted | 0 | |
Deleted | 6 | |
Risk group | ||
Low risk | 1-2 | 95 |
Intermediate risk | 3-5 | 86 |
High risk | 6-10 | 67 |
Very-high risk | 11-14 | 18 |
ECOG PS, Eastern Cooperative Oncology Group performance status; GCLLSG, German CLL Study Group.